What is the difference between cystinosis and cystinuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Cystinosis and cystinuria are two distinct genetic disorders with different pathophysiologies and clinical manifestations, requiring different management approaches to improve morbidity, mortality, and quality of life. Cystinosis is a lysosomal storage disease caused by mutations in the CTNS gene, leading to cystine accumulation within lysosomes of cells throughout the body, resulting in progressive organ damage, particularly to the kidneys, eyes, and thyroid [@\1@]. In contrast, cystinuria is a transport disorder affecting the kidneys' ability to reabsorb cystine and dibasic amino acids in the proximal tubule, causing excessive cystine excretion in urine and leading to recurrent kidney stone formation [@\2@].

Key differences in clinical presentation

  • Cystinosis: characterized by renal Fanconi syndrome in childhood, with symptoms including polyuria, polydipsia, growth retardation, and eventual kidney failure
  • Cystinuria: patients experience typical stone symptoms like flank pain, hematuria, and urinary tract infections

Management approaches

  • Cystinosis: treatment involves cysteamine (Cystagon or Procysbi) to remove cystine from lysosomes, and kidney transplantation for end-stage renal disease
  • Cystinuria: management focuses on preventing stone formation through high fluid intake, urinary alkalinization with potassium citrate, and sometimes thiol-binding drugs like d-penicillamine or tiopronin to increase cystine solubility [@\1@, @\2@]

Importance of dietary modifications

  • Patients with cystinuria should limit sodium and protein intake, as high fluid intake is crucial to decrease urinary cystine concentration below 250 mg/L [@\1@]
  • A reasonable goal for sodium intake in individuals with cystinuria is 100 mEq (2,300 mg) or less daily [@\1@]

Pharmacological therapy

  • Tiopronin is possibly more effective and associated with fewer adverse events than d-penicillamine and should be considered first for patients with cystine stones who are unresponsive to dietary modifications and urinary alkalinization [@\2@]

From the Research

Differences between Cystinosis and Cystinuria

  • Cystinosis is a rare autosomal-recessive lysosomal storage disease caused by mutations in the CTNS gene, leading to lysosomal cystine accumulation 1, 2, 3.
  • Cystinuria, on the other hand, is an inherited disorder of the dibasic amino acid transport system in the proximal tubule and the small intestine, caused by mutations in the SLC3A1 and SLC7A9 genes 4.
  • The main difference in pathophysiologic mechanisms is that cystinosis is a disease of cystine storage, while cystinuria is a disease of renal tubular cystine transport 5.
  • Cystinosis uniformly results in the need for renal allograft, despite recent advances in medical therapy, while cystinuria has a variable severity of expression and may be amenable to long-term medical treatment in some patients 5.
  • Cystinosis affects multiple organs, including the kidneys, eyes, thyroid, pancreas, gonads, muscles, and CNS, while cystinuria primarily affects the kidneys and is characterized by stone formation due to the inability of renal tubules to reabsorb cystine 1, 3, 4.

References

Research

Effects of long-term cysteamine treatment in patients with cystinosis.

Pediatric nephrology (Berlin, Germany), 2019

Research

Pharmacological treatment of nephropathic cystinosis with cysteamine.

Expert opinion on pharmacotherapy, 2004

Research

Cystinosis: a review.

Orphanet journal of rare diseases, 2016

Research

Cystinosis and cystinuria: differences in outcome.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.